Movers and SHAKERS
Helix Biopharma (HBPCF)(HBP:CA)
Q1 F2021: Business Update
As of April 24, 2020, Noble Capital Markets research on Helix Biopharma is published under ticker symbols (HBPCF and HBP:CA). The price target is in USD and based on ticker symbol HBPCF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q1 F2021 financial results. Helix reported financial results for the first quarter of fiscal 2021 ending October 31, 2020. Net operating loss was $0.2 million (loss from operations $2.4 million and gain from discontinued operations of $2.2 million) for the quarter with $1.1 million in research and development expenses and $1.3 million in general and administrative expenses. Helix reported ($0.02) EPS.
Near-term value drivers. We believe data updates from two clinical trials in pancreatic cancer and non-small cell lung cancer would be the major value generators for the company. The company also intends to raise capital and up-list on the Nasdaq stock exchange. We expect this to generate traction and visibility by US investors ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.